PPARα agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes

Diabetes

Volumn 56, Issue 6, 2007, Pages 1662-1670

  Nakamachi, Takafumi ^a   Nomiyama, Takashi ^a   Gizard, Florence ^a   Heywood, Elizabeth B ^a   Jones, Karrie L ^a   Zhao, Yue ^a   Fuentes, Lucia ^b,c,d   Takebayashi, Kohzo ^e   Aso, Yoshimasa ^e   Staels, Bart ^b,c,d   Inukai, Toshihiko ^e   Bruemmer, Dennis ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b INSTITUT PASTEUR DE LILLE   (France)

^c INSERM   (France)

^d UNIV LILLE   (France)

^e DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; BEZAFIBRATE; FENOFIBRIC ACID; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIRINIXIC ACID; PROTEIN C FOS; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1; ANTILIPEMIC AGENT; LIGAND; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ANIMAL CELL; ARTICLE; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; ANIMAL; BLOOD; CELL LINE; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MONOCYTE; PHYSIOLOGY; PLASMID; POLYMERASE CHAIN REACTION;

ANIMALS; ANTILIPEMIC AGENTS; BEZAFIBRATE; CELL LINE; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MACROPHAGES; MICE; MONOCYTES; OSTEOPONTIN; PLASMIDS; POLYMERASE CHAIN REACTION; PPAR ALPHA; PYRIMIDINES; TRANSFECTION;

EID: 34249656915     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1177     Document Type: Article

References (34)

1. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860-864, 2000
2. Denhardt DT, Giachelli CM, Rittling SR: Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41:723-749, 2001
3. Giachelli CM, Steitz S: Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 19:615-622, 2000
4. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92:1686-1696, 1993
5. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA: Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112:1318-1331, 2003
6. Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T, Akino M, Sugawara T, Morimoto J, Kimura C, Kon S, Denhardt D, Kitabatake A, Uede T: Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23:1029-1034, 2003
7. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, Ohsuzu F: Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 170:333-337, 2003
8. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, Geroldi D: Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 27:802-807, 2006
9. Yamaguchi H, Igarashi M, Hirata A, Tsuchiya H, Sugiyama K, Morita Y, Jimbu Y, Ohnuma H, Daimon M, Tominaga M, Kato T: Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J 51:499-504, 2004
10. Takemoto M, Yokote K, Yamazaki M, Ridall AL, Butler WT, Matsumoto T, Tamura K, Saito Y, Mori S: Enhanced expression of osteopontin by high glucose: involvement of osteopontin in diabetic macroangiopathy. Ann N Y Acad Sci 902:357-363, 2000
11. Bidder M, Shao J-S, Charlton-Kachigian N, Loewy AP, Semenkovich CF, Towler DA: Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J Biol Chem 277:44485-44496, 2002
12. Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF: Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 273:30427-30434, 1998
13. deBlois D, Lombardi DM, Su EJ, Clowes AW, Schwartz SM, Giachelli CM: Angiotensin II induction of osteopontin expression and DNA replication in rat arteries. Hypertension 28:1055-1063, 1996
14. Marx N, Duez H, Fruchart J-C, Staels B: Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94:1168-1178, 2004
15. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart J-C, Chapman J, Najib J, Staels B: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273:25573-25580, 1998
16. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94:4312-4317, 1997
17. Lefebvre P, Chinetti G, Fruchart J-C, Staels B: Sorting out the roles of PPAR{alpha} in energy metabolism and vascular homeostasis. J Clin Invest 116:571-580, 2006
18. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J, the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999
19. Ericsson C-G, de Faire U, Grip L, Svane B, Hamsten A, Nilsson J: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347:849-853, 1996
20. Teissier E, Nohara A, Chinetti G, Paumelle R, Cariou B, Fruchart J-C, Brandes RP, Shah A, Staels B: Peroxisome proliferator-activated receptor {alpha} induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-{alpha} activation properties. Circ Res 95:1174-1182, 2004
21. Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart J-C, Torpier G, Staels B: PPAR{alpha} inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest 115:3228-3238, 2005
22. Ogawa D, Stone JF, Takata Y, Blaschke F, Chu VH, Towler DA, Law RE, Hsueh WA, Bruemmer D: Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ Res 96:e59-e67, 2005
23. Vordermark D, Said H, Katzer A, Kuhnt T, Hansgen G, Dunst J, Flentje M, Bache M: Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 6:207, 2006
24. Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T: Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 28:2211-2216, 2005
25. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest 116:1793-1801, 2006
26. Oyama Y, Akuzawa N, Nagai R, Kurabayashi M: PPAR{gamma} ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. Circ Res 90:348-355, 2002
27. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B: Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 269:31012-31018, 1994
28. Semenkovich CF: Insulin resistance and atherosclerosis. J Clin Invest 116:1813-1822, 2006
29. Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M, Iemitsu M, Sudo T, Goto K, Yamaguchi I: Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-{alpha} partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation 109:904-910, 2004
30. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart J-C, Tedgui A, Haegeman G, Staels B: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappa B and AP-1. J Biol Chem 274:32048-32054, 1999
31. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137, 2002
32. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 115:1111-1119, 2005
33. Panda D, Kundu GC, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K, Mukherjee AB: Potential roles of osteopontin and alphaVbeta 3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci U S A 94:9308-9313, 1997
34. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M: Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 152:353-358, 1998